



## HELINN WILL PRESENT AT THE 26<sup>th</sup> ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE, SAN FRANCISCO

Lugano, December 18, 2007 – **Helsinn Healthcare S.A.** today announced that its CEO, Dr. Riccardo Braglia will attend the 26<sup>th</sup> Annual J.P. Morgan Healthcare Conference in San Francisco, US, and present an overview of the Helsinn group, of its products and its corporate goals on January 9, 2008 at 10:30am local time (6.30pm GMT, 7:30pm Swiss time).

### **About HELSINN HEALTHCARE**

HELINN is a privately owned pharmaceutical group with headquarters in Switzerland. Helsinn's core business is the licensing of pharmaceuticals in therapeutic areas (oncology, cancer supportive care, pain and inflammation, gastrointestinal).

The company's business strategy is to in-license early-stage new chemical entities and to complete their development from the performance of pre-clinical/clinical studies and CMC development to the attainment of market approvals in strategic markets (U.S. and Europe). Helsinn's products are eventually out-licensed to its worldwide consolidated network of partners for distribution. Helsinn's key products in the US are Aloxi<sup>®</sup> (palonosetron) distributed by MGI Pharma and Gelclair<sup>®</sup>

distributed by EKR Therapeutics Inc., US. The active pharmaceutical ingredients and the drug products are manufactured at Helsinn's cGMP facilities and supplied worldwide to its customers. Helsinn's chemical business focuses on the pharmaceutical chemical process development and manufacturing of advanced intermediates, Active Pharmaceutical Ingredients (APIs) and High Potency Active Ingredients (HPAIs) for both the Helsinn group and its outsourcing partners. For more information about Helsinn, please visit [www.helsinn.com](http://www.helsinn.com)

### **Helsinn Healthcare Contact:**

**Alessandro Bossi, D.V.M.**

Director, Business Development

Tel: (+41) 91-9852121

E-mail: [ba@helsinn.com](mailto:ba@helsinn.com)